Success Metrics

Clinical Success Rate
84.2%

Based on 16 completed trials

Completion Rate
84%(16/19)
Active Trials
9(27%)
Results Posted
94%(15 trials)
Terminated
3(9%)

Phase Distribution

Ph phase_3
10
30%
Ph phase_4
6
18%
Ph phase_2
9
27%

Phase Distribution

0

Early Stage

9

Mid Stage

16

Late Stage

Phase Distribution25 total trials
Phase 2Efficacy & side effects
9(36.0%)
Phase 3Large-scale testing
10(40.0%)
Phase 4Post-market surveillance
6(24.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

84.2%

16 of 19 finished

Non-Completion Rate

15.8%

3 ended early

Currently Active

9

trials recruiting

Total Trials

33

all time

Status Distribution
Active(13)
Completed(16)
Terminated(3)
Other(1)

Detailed Status

Completed16
Recruiting6
Not yet recruiting3
Active, not recruiting3
Terminated3
Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials
33
Active
9
Success Rate
84.2%
Most Advanced
Phase 4

Trials by Phase

Phase 29 (36.0%)
Phase 310 (40.0%)
Phase 46 (24.0%)

Trials by Status

not_yet_recruiting39%
active_not_recruiting39%
enrolling_by_invitation13%
completed1648%
terminated39%
unknown13%
recruiting618%

Recent Activity

Clinical Trials (33)

Showing 20 of 33 trialsScroll for more
NCT05156398Phase 3

Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects

Recruiting
NCT06616194Phase 3

A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine

Recruiting
NCT05046613

Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant

Recruiting
NCT06641466Phase 3

A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine

Recruiting
NCT06985342Phase 4

Acute Migraine Treatment in the ED With Gepants

Terminated
NCT05509400Phase 4

Efficacy and Tolerability of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use

Completed
NCT06439628

ARISE-A Chinese Real-world Study of Rimegepant for the Acute Treatment of Migraine

Active Not Recruiting
NCT06680206

Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey

Completed
NCT05810038Phase 3

A Study to Learn About the Safety and Effects of Rimegepant to Prevent Migraine in Chinese Subjects.

Completed
NCT05264714Phase 2

Cluster Headache Treatment With Rimegepant

Completed
NCT05198245

Study of Pregnancy Outcomes in Women Exposed to Rimegepant During Pregnancy

Active Not Recruiting
NCT05399485Phase 3

Efficacy and Safety Study of Rimegepant for Migraine Prevention in Japanese Subjects (Japan Only)

Completed
NCT06212661

Migraine Medication Effects on Urinary Symptoms

Enrolling By Invitation
NCT06473597Phase 4

A Comparison of Nurtec ODT to Maxalt MLT-ODT in Adult ED Patients With Migraine Headache

Recruiting
NCT05207865Phase 4

Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine Prevention

Completed
NCT05518123Phase 4

Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications

Completed
NCT04629950Phase 2

Rimegepant in Moderate Plaque-type Psoriasis

Completed
NCT06992674Phase 2

The R-E-V-I-V-A-L Study

Active Not Recruiting
NCT06999252Phase 2

Rimegepant Combined With PD-1 in Liver Metastasis Colorectal Cancer Patients

Not Yet Recruiting
NCT06748664Phase 2

A Clinical Trial of Rimegepant for Vestibular Migraine Evaluation: Pre-experiment

Not Yet Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
33